FEB 09, 2021 9:00 AM PST

Development and analytical validation of prognostic biomarkers for metastasis

Sponsored by: Visiopharm®
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract
Date:  February 9, 2021
Time: 9:00am (PST),  12:00pm (EST),  6:00pm (CET)
 
90% of breast cancer mortality is caused by distant metastasis, a process that involves both dissemination of cancer cells to distant sites as well as their proliferation after arrival. However, prognostic assays currently used in the clinic are based on proliferation and do not measure tumor cell dissemination potential. Based on intravital imaging of tumor cell dissemination in live animals, we previously reported two biomarkers for the development of distant metastasis: TMEM Score and MenaCalc. TMEM Score is based upon the density of Tumor Microenvironment of Metastasis (TMEM) doorways, portals for cancer cell intravasation and dissemination formed by the confluence of a Mena overexpressing tumor cell, a pro-angiogenic macrophage, and an endothelial cell. MenaCalc is a pattern of expression of the actin-regulatory protein Mena which leads tumor cells to undergo epithelial-to-mesenchymal transition (EMT) and become highly motile. Using digital pathology, we analytically validated an automated analysis of TMEM doorways that reduced pathologist time by an order of magnitude and enabled the rapid clinical validation of TMEM Score. While TMEM score has been validated for prognosticating metastatic outcome in HR+/HER2- patients, statistical significance was not observed in patients with triple negative or HER2+ breast cancers. Furthermore, MenaCalc has been shown to be prognostic in some cohorts of patients with triple negative disease but the prognostic value of MenaCalc in HR+ disease is still unclear. Since TMEM doorways and MenaCalc are mechanistically linked (but independent) biomarkers, we investigated if a combined TMEM-MenaCalc biomarker can improve the prognostication ability of either biomarker alone. Again, using digital pathology, we evaluated several different methods of combining TMEM and MenaCalc scores to create a multiparameter quantitative analysis with dramatically improved prognostic ability for distant metastasis in breast cancer patients.
 
Learning Objectives
  • Discuss the process of tumor cell dissemination from breast tumors.
  • Summarize how live imaging studies are able to discover mechanisms of metastasis which can then be turned into prognostic biomarkers for metastasis.
  • Outline how digital whole slide scanning and digital pathology can be used to automate as well as analytically and clinically validate prognostic biomarkers.
 
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
DEC 09, 2021 6:00 AM PST
C.E. CREDITS
DEC 09, 2021 6:00 AM PST
Date: December 9, 2021 Time: 6:00am (PDT), 9:00 am (EDT) As the number of biotherapeutic candidates in development is increasing, the requirements of analytical tools to understand the molec...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
Loading Comments...
Show Resources